Synonyms：
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-iododecane
2-(perfluorooctyl)ethyl iodide
1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro-10-iodo-decane
1-iodo-1H,1H,2H,2H-perfluorodecane
1-perfluorooctyl-2-iodoethane
1H,1H,2H,2H-Perfluoro-1-decyl iodide
1H,1H,2H,2H-Heptadecafluorodecyl Iodide
1H,1H,2H,2H-perfluoro-1-iododecane
1H,1H,2H,2H-perfluorodecyl iodide
1H,1H,2H,2H-Heptadecafluoro-1-iododecane
Molecular Formula: C10H4F17I
Molecular weight：574.01600
Appearance and properties: yellow-brown solid
Density: 1.88g/ml
Boiling point: 178 °C
Melting point: 54-58 °C(lit.)
Flash point: 92-96°C/12mm
Refractive index: 1.3388 (60ºC)
Stability: Stable.
Storage conditions: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from light.
Our company is committed to establishing a complete fluorochemical products and technology platform to provide customers with convenient one-stop services. Our products are widely used in the manufacture of new materials, pharmaceutical research and development and the development of new pesticides. The fluorine product categories include fluorine-containing material raw materials, fluorinated reagents, fluorine-containing building blocks, fluorine-containing reagents and fluorine-containing gases for synthesis. Shanghai Fluorine Technology will strive to build a complete industrial chain from fluorine-containing raw material procurement, fluorination technology research and development, fluorine-containing product production, fluorine-containing product storage, fluorine-containing product quality control and fluorine-containing product application.
We are professional 1-Iodo-1H,1H,2H,2H-perfluorodecane manufacturer and 1H,1H,2H,2H-Perfluoro-1-iododecane supplier in China, We offer quality 1H,1H,2H,2H-Heptadecafluoro-1-iododecane you can fully trust, also we have India factory and producer of 1-Iodo-1H,1H,2H,2H-perfluorodecane,Pls send inquiry of 1H,1H,2H,2H-Heptadecafluoro-1-iododecane CAS:2043-53-0 to info@nbinno.com if you have any interests, thank you!
Related News: Biogen hiked its revenue guidance for the year, saying it expects total sales of $10.65 billion to $10.85 billion this year. That’s up from its previous estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” revenue from Aduhelm in 2021, ramping up thereafter, the company said.oxo-diphenyl-(2,3,5,6-tetrachloropyridin-4-yl)imino-λ(sup)6(/sup)-sulfane manufacturer This scheme has a total outlay of Rs. 6,940 crore for the entire period. The applications under four different target segments were invited on November 30, 2020. Of the 215 applications, 36 products across the 4 target segments were granted. Butanoic acid, 4-amino-2-azido-4-oxo-, (2S)- supplier Along with Natural Biogenix were Symbiotec Pharmalab, Macleods Pharmaceutical, Optimus Drugs, Sudarshan Pharma, Saraca Laboratories, Emmennar Pharma, Hindys Lab, Aarti Speciality, Meghmani LLP and and Sadhana Nitro Chem. 4-amino-6-(4-morpholino)-2-phenylpyrimidine manufacturer Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients.
